Respiratory Syncytial Virus Infections
Conditions
Brief summary
The purpose of this study was to evaluate the safety, infectivity, and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants and children 6 to 24 months of age. This study was a companion study to CIR 313.
Detailed description
Human respiratory syncytial virus (RSV) is the most common viral cause of serious acute lower respiratory illness (LRI) in infants and children under 5 years of age worldwide. This study evaluated the safety, infectivity, and immunogenicity of a single dose of RSV D46/NS2/N/ΔM2-2-HindIII, a recombinant live-attenuated RSV vaccine, in RSV-seronegative infants and children 6 to 24 months of age. Participants were randomly assigned to receive a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine or placebo (administered as nose drops) at study entry (Day 0). Participants could be enrolled in the study outside of RSV season (between April 1 and October 14 for most sites or-for sites with local RSV seasons that start earlier-as specified on a site-by-site basis in the Manual Of Procedures). All participants remained on study until they completed the post-RSV season visit between April 1 and April 30 in the calendar year following enrollment. Participants' total study duration was between 6 and 13 months, depending on when they enrolled in the study. Participants attended several study visits throughout the study, which included physical examinations, blood collection, and nasal washes. Participants' parents or guardians were contacted by study staff at various times during the study to monitor participants' health.
Interventions
BIOLOGICALD46/NS2/N/ΔM2-2-HindIII
10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
BIOLOGICALPlacebo
Isotonic diluent; administered as nose drops
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 24 Months
Healthy volunteers
Yes
Inclusion criteria
* Good health based on review of the medical record, history, and physical examination, without evidence of chronic disease. * Parents/guardians willing and able to provide written informed consent as described in the protocol. * Seronegative for RSV antibody, defined as a serum RSV-neutralizing antibody titer less than 1:40 at screening from a sample collected no more than 42 days prior to inoculation. Note: results from specimens collected during screening for any study of an RSV vaccine developed by the Laboratory of Infectious Diseases (LID) (NIAID, NIH) were acceptable as long as within the 42-day window. * Growing at a normal velocity for age (as demonstrated on a standard growth chart) AND * If less than 1 year of age: current height and weight above the 5th percentile * If 1 year of age or older: current height and weight above the 3rd percentile for age. * Received routine immunizations appropriate for age (as per national Center for Disease Control Advisory Committee on Immunization Practices \[ACIP\]). Note: if rotavirus immunization was delayed, catch-up rotavirus immunization was indicated only if the participant was age-eligible per ACIP. * Expected to be available for the duration of the study. * If born to an HIV-infected woman, participant must not have been breastfed and must have had documentation of 2 negative HIV nucleic acid (RNA or DNA) test results from samples collected on different dates with both collected when greater than or equal to 4 weeks of age and at least one collected when greater than or equal to 16 weeks of age, and no positive HIV nucleic acid (RNA or DNA) test; or 2 negative HIV antibody tests, both from samples collected at greater than or equal to 24 weeks of age.
Exclusion criteria
* Known or suspected HIV infection or impairment of immunological functions. * Receipt of immunosuppressive therapy, including any systemic, including either nasal or inhaled, corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment was not an exclusion. * Bone marrow/solid organ transplant recipient. * Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities. * Previous receipt of a licensed or investigational RSV vaccine (or placebo in any IMPAACT RSV study) or previous receipt of or planned administration of any anti-RSV product (such as ribavirin or RSV immunoglobulin \[IG\] or RSV monoclonal antibody \[mAb\]). * Previous anaphylactic reaction. * Previous vaccine-associated adverse reaction that was Grade 3 or above. * Known hypersensitivity to any study product component. * Heart disease. Note: Participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled. * Lung disease, including any history of reactive airway disease or medically diagnosed wheezing. * Member of a household that contained, or would contain, an infant who was less than 6 months of age at the enrollment date through Day 28. * Member of a household that contains another child who was, or was scheduled to be, enrolled in IMPAACT 2011, 2012 or 2013 or another study evaluating an intranasal live-attenuated RSV vaccine, AND there had been or would be an overlap in residency during that other child's participation in the study's Acute Phase (Days 0 to 28). * Member of a household that contained an immunocompromised individual, including, but not limited to: * a person who was greater than or equal to 6 years of age with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell count less than 300 cells/mm\^3. CD4 T lymphocyte count must have been measured within 6 months prior to enrollment, or * a person age 1 year up to less than 6 years with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell percentage less than 25 or CD4 T lymphocyte count less than 750 cells/mm\^3 (if both values are available, use the lower of the two). CD4 T lymphocyte parameter must have been measured within the 6 months prior to enrollment; or * a person age less than 1 year with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell percentage less than 30 or CD4 T lymphocyte count less than 1000 cells/mm\^3 (if both values are available, use the lower of the two). CD4 T lymphocyte parameter must have been measured within the 6 months prior to enrollment; or * a person who had received chemotherapy within the 12 months prior to enrollment; or * a person receiving immunosuppressant agents; or * a person living with a solid organ or bone marrow transplant. Verbal report of CD4 T cell lymphocyte was sufficient documentation if the parent/guardian was confident of history. * Attended a daycare facility and shared a room with infants less than 6 months of age, and parent/guardian was unable or unwilling to suspend daycare for 28 days following inoculation. * Any of the following events at the time of enrollment: * fever (rectal temperature of greater than or equal to 100.4°F (38°C)), or * upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or * nasal congestion significant enough to interfere with successful inoculation, or * otitis media. * Receipt of the following prior to enrollment: * any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or * any live vaccine, other than rotavirus vaccine, within the 28 days prior, or * another investigational vaccine or investigational drug within 28 days prior * Scheduled administration of the following after planned inoculation: * inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or * any live vaccine other than rotavirus in the 28 days after, or * another investigational vaccine or investigational drug in the 56 days after * Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months * Receipt of any of the following medications within 3 days of study enrollment: * systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or * intranasal medications, or * other prescription medication except as listed below Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents. * Receipt of salicylate (aspirin) or salicylate-containing products within the 28 days prior to enrollment. * Born at less than 34 weeks gestation. * Born at less than 37 weeks gestation and less than 1 year of age at the time of enrollment. * Suspected or documented developmental disorder, delay, or other developmental problem. * Previous receipt of supplemental oxygen therapy in a home setting.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) | Measured at Day 56 | Immunogenicity was assessed at approximately 2 months post-inoculation (Study Day 56). |
| Number of Participants Infected With RSV Vaccine Virus | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 for nasal washes, and at Days 0, 56 for serum RSV-neutralizing antibodies | Defined as 1) vaccine virus identified in a nasal wash from Study Day 0-28 (a binary outcome based on nasal washes) and/or 2) greater than or equal to 4-fold rise in RSV-neutralizing antibody titer from Study Day 0 and 56. |
| Peak Titer of Vaccine Virus Shed | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 | This is the highest value per participant of the titer of vaccine virus shed. It was measured by culture. Only participants who met the definition of infection with vaccine virus were included. |
| Duration of Vaccine Virus Shedding in Nasal Washes | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28. Last day positive is reported. | Determined separately by a) culture and b) reverse transcription polymerase chain reaction (RT-PCR) |
| Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer | Measured at Day 0 and Day 56 | Immunogenicity was assessed pre-inoculation, and at approximately 2 months post-inoculation (Study Day 56). Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points. |
| Number of Participants With Solicited Adverse Events (AEs) by Grade | Measured from Day 0 through Day 28 | Solicited adverse events included fever; otitis media; upper respiratory illness (URI); lower respiratory illness (LRI) and cough (without LRI). The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each solicited AE category, and that was in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 3 and Table 4 in the protocol document. |
| Number of Participants With Unsolicited AEs by Grade | Measured from Day 0 through Day 28 | Unsolicited adverse events were other events, not included in the solicited AEs. The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each unsolicited AE category, and that was in the line corresponding to the highest grade adverse event they had in that category. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by DAIDS AE Grading table v2.0 (see References). |
| Number of Participants With Serious Adverse Events (SAEs) | Measured from Day 0 through Day 56 | A Serious Adverse Event (SAE) was an AE, whether considered related to the study product or not, that: * Resulted in death during the period of protocol-defined surveillance * Was life threatening: defined as an event in which the patient was at immediate risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death were it more severe * Required inpatient hospitalization (or prolongation of existing hospitalization): defined as at least an overnight stay in the hospital or emergency ward for treatment that would have been inappropriate if administered in the outpatient setting * Resulted in a persistent or significant disability/incapacity * Was a congenital anomaly or birth defect * Was an important medical event that might not be immediately life threatening or result in death or hospitalization but might jeopardize the patient or might require intervention to prevent one of the outcomes listed above. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Measured from November 1st through participant's post-RSV season surveillance visit | The number of participants who had RSV-associated, medically attended, acute respiratory illness (RSV-MAARI) or RSV-associated, medically attended, acute lower respiratory illness (RSV-MAALRI) among those who had RSV detected in nasal washes or greater than or equal to 4 fold rise in serum antibodies during the subsequent RSV season were presented. |
| Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Measured through participant's last study visit, up to a total of 6 to 13 months depending on when participants enrolled in the study | Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included. RSV-neutralizing antibody titers were measured pre- and post-RSV surveillance season. |
| Number of Participants With B Cell Responses to Vaccine | Measured at day 0 and Day 56 | A B cell response to vaccine is indicated by a greater than or equal to 4-fold change in serum antibody titers to RSV F glycoprotein between the pre- and post-inoculation time points. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Mucosal Antibody Responses to Vaccine | Measured at Day 0, 28 and 56 | Determined from nasal wash samples. This outcome has been changed from a secondary outcome measure to an 'other pre-specified' outcome measure. Since this outcome measure relies on previously untested assays to reliably quantify RSV specific mucosal antibodies from nasal wash samples, it was changed to other pre-specified to fit with its intended analysis type. |
Countries
United States
Participant flow
Recruitment details
Recruitment period was from April to October 2017. Participants were recruited from medical clinics.
Participants by arm
| Arm | Count |
|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
D46/NS2/N/ΔM2-2-HindIII: 10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops | 21 |
| Placebo Participants received a single dose of placebo at study entry (Day 0).
Placebo: Isotonic diluent; administered as nose drops | 11 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Placebo | Total | RSV D46/NS2/N/ΔM2-2-HindIII Vaccine |
|---|---|---|---|
| Age, Continuous | 9 months | 9 months | 9 months |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants | 18 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 14 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 10 Participants | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) White | 6 Participants | 20 Participants | 14 Participants |
| Region of Enrollment United States | 11 participants | 32 participants | 21 participants |
| Serum RSV-neutralizing antibody titers | 2.3 log 2 titers | 2.3 log 2 titers | 2.3 log 2 titers |
| Sex: Female, Male Female | 8 Participants | 21 Participants | 13 Participants |
| Sex: Female, Male Male | 3 Participants | 11 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 11 |
| other Total, other adverse events | 17 / 21 | 10 / 11 |
| serious Total, serious adverse events | 0 / 21 | 0 / 11 |
Outcome results
Primary
Duration of Vaccine Virus Shedding in Nasal Washes
Determined separately by a) culture and b) reverse transcription polymerase chain reaction (RT-PCR)
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28. Last day positive is reported.
Population: Only participants who met the definition of infection with vaccine virus were included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Duration of Vaccine Virus Shedding in Nasal Washes | Culture positive | 10 days |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Duration of Vaccine Virus Shedding in Nasal Washes | RT-PCR positive | 14 days |
Primary
Number of Participants Infected With RSV Vaccine Virus
Defined as 1) vaccine virus identified in a nasal wash from Study Day 0-28 (a binary outcome based on nasal washes) and/or 2) greater than or equal to 4-fold rise in RSV-neutralizing antibody titer from Study Day 0 and 56.
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 for nasal washes, and at Days 0, 56 for serum RSV-neutralizing antibodies
Population: Study participants who received inoculation were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants Infected With RSV Vaccine Virus | 21 Participants |
| Placebo | Number of Participants Infected With RSV Vaccine Virus | 0 Participants |
Primary
Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer
Immunogenicity was assessed pre-inoculation, and at approximately 2 months post-inoculation (Study Day 56). Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points.
Time frame: Measured at Day 0 and Day 56
Population: Study participants who received inoculation were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer | 20 Participants |
| Placebo | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer | 0 Participants |
p-value: <0.001Fisher Exact
Primary
Number of Participants With Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) was an AE, whether considered related to the study product or not, that: * Resulted in death during the period of protocol-defined surveillance * Was life threatening: defined as an event in which the patient was at immediate risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death were it more severe * Required inpatient hospitalization (or prolongation of existing hospitalization): defined as at least an overnight stay in the hospital or emergency ward for treatment that would have been inappropriate if administered in the outpatient setting * Resulted in a persistent or significant disability/incapacity * Was a congenital anomaly or birth defect * Was an important medical event that might not be immediately life threatening or result in death or hospitalization but might jeopardize the patient or might require intervention to prevent one of the outcomes listed above.
Time frame: Measured from Day 0 through Day 56
Population: Study participants who received inoculation were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
| Placebo | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
Primary
Number of Participants With Solicited Adverse Events (AEs) by Grade
Solicited adverse events included fever; otitis media; upper respiratory illness (URI); lower respiratory illness (LRI) and cough (without LRI). The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each solicited AE category, and that was in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 3 and Table 4 in the protocol document.
Time frame: Measured from Day 0 through Day 28
Population: Study participants who received inoculation were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 1 | 12 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Did not have this AE | 21 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Did not have this AE | 21 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Did not have this AE | 17 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 1 | 3 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 1 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 2 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Did not have this AE | 6 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 1 | 15 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 1 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Did not have this AE | 9 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Did not have this AE | 9 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 1 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 2 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Did not have this AE | 10 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 1 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 3 | 0 Participants |
90% CI: [56, 90]
90% CI: [3, 47]
Primary
Number of Participants With Unsolicited AEs by Grade
Unsolicited adverse events were other events, not included in the solicited AEs. The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each unsolicited AE category, and that was in the line corresponding to the highest grade adverse event they had in that category. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by DAIDS AE Grading table v2.0 (see References).
Time frame: Measured from Day 0 through Day 28
Population: Study participants who received inoculation were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Sneezing | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Did not have this AE | 19 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 1 | 2 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Irritability | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Did not have this AE | 17 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 1 | 4 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 4 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Did not have this AE | 20 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 1 | 1 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 2 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 3 | 0 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Irritability | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Did not have this AE | 10 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 1 | 1 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Sneezing | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Irritability | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Diarrhea, vomiting | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Sneezing | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Epistaxis | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Eczema, Diaper rash | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Nasal congestion | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Middle ear effusion | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Unsolicited AEs by Grade | Lymphadenopathy | Grade 4 | 0 Participants |
90% CI: [10, 44]
90% CI: [0, 36]
Primary
Peak Titer of Vaccine Virus Shed
This is the highest value per participant of the titer of vaccine virus shed. It was measured by culture. Only participants who met the definition of infection with vaccine virus were included.
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28
Population: Only participants who met the definition of infection with vaccine virus were included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Peak Titer of Vaccine Virus Shed | 3.5 log10 PFU/mL |
Primary
Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)
Immunogenicity was assessed at approximately 2 months post-inoculation (Study Day 56).
Time frame: Measured at Day 56
Population: Study participants who received inoculation were included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) | 15.7 log 2 titers |
| Placebo | Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) | 8.1 log 2 titers |
p-value: <0.001Log Rank
Secondary
Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season.
Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included. RSV-neutralizing antibody titers were measured pre- and post-RSV surveillance season.
Time frame: Measured through participant's last study visit, up to a total of 6 to 13 months depending on when participants enrolled in the study
Population: Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Pre-RSV surveillance | 6.3 log 2 titers |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Post-RSV Surveillance | 10.4 log 2 titers |
| Placebo | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Pre-RSV surveillance | 2.3 log 2 titers |
| Placebo | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Post-RSV Surveillance | 7.1 log 2 titers |
Secondary
Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season
The number of participants who had RSV-associated, medically attended, acute respiratory illness (RSV-MAARI) or RSV-associated, medically attended, acute lower respiratory illness (RSV-MAALRI) among those who had RSV detected in nasal washes or greater than or equal to 4 fold rise in serum antibodies during the subsequent RSV season were presented.
Time frame: Measured from November 1st through participant's post-RSV season surveillance visit
Population: Only participants who had RSV detected in nasal washes or greater than or equal to 4 fold rise in serum antibodies during the subsequent RSV season were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | RSV-MAARI | 2 Participants |
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | RSV-MAALRI | 0 Participants |
| Placebo | Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | RSV-MAARI | 3 Participants |
| Placebo | Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | RSV-MAALRI | 1 Participants |
Secondary
Number of Participants With B Cell Responses to Vaccine
A B cell response to vaccine is indicated by a greater than or equal to 4-fold change in serum antibody titers to RSV F glycoprotein between the pre- and post-inoculation time points.
Time frame: Measured at day 0 and Day 56
Population: All participants who received inoculation were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Number of Participants With B Cell Responses to Vaccine | 21 Participants |
| Placebo | Number of Participants With B Cell Responses to Vaccine | 0 Participants |
Other Pre-specified
Frequency of Mucosal Antibody Responses to Vaccine
Determined from nasal wash samples. This outcome has been changed from a secondary outcome measure to an 'other pre-specified' outcome measure. Since this outcome measure relies on previously untested assays to reliably quantify RSV specific mucosal antibodies from nasal wash samples, it was changed to other pre-specified to fit with its intended analysis type.
Time frame: Measured at Day 0, 28 and 56